MPGN
MCID: MMB001
MIFTS: 56

Membranoproliferative Glomerulonephritis (MPGN)

Categories: Immune diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Membranoproliferative Glomerulonephritis

MalaCards integrated aliases for Membranoproliferative Glomerulonephritis:

Name: Membranoproliferative Glomerulonephritis 12 20 36 15
Mesangiocapillary Glomerulonephritis 20 58 29 6
Primary Membranoproliferative Glomerulonephritis 20 58
Glomerulonephritis, Membranoproliferative 44 70
Glomerulonephritis Membranoproliferative 54
Chronic Glomerulonephritis, Lobular 12
Lobular Glomerulonephritis 12
Primary Mpgn 58
Mpgn 20

Characteristics:

Orphanet epidemiological data:

58
primary membranoproliferative glomerulonephritis
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:2920
KEGG 36 H01726
MeSH 44 D015432
NCIt 50 C34644
SNOMED-CT 67 80321008
MESH via Orphanet 45 D015432
ICD10 via Orphanet 33 N03.5
UMLS via Orphanet 71 C0017662
Orphanet 58 ORPHA54370
UMLS 70 C0017662

Summaries for Membranoproliferative Glomerulonephritis

KEGG : 36 Membranoproliferative glomerulonephritis (MPGN) represents a pattern of glomerular injury, characterized by mesangial proliferation and expansion, lobularization of the glomerular tufts and double contours. Classification of MPGN has been updated in the 2010s, and is now categorized according to the immunofluorescence microscopy findings. Until recently, the MPGNs have been distinguished according to the histological and ultra structural findings and were classified as MPGN type I, type II and type III. A new terminology that distinguishes immunoglobulin-mediated MPGN (ie, the former type I) from complement-mediated MPGN has been proposed. Immune-complexes mediated MPGN is caused by the deposition of immunocomplexes in the glomeruli. The immunocomplexes activate the classical pathway (CP) of complement and cause the deposition of complement factors or of the membrane attack complex (MAC) in the mesangium and capillary loops. The most frequent underlying disorders associated with immune complex MPGN include chronic infections, autoimmune diseases, and monoclonal gammopathies. The complement-mediated MPGN, termed C3 glomerulopathy, is characterised by defects in the alternative pathway of complement, in particular of factor H, or autoantibodies to complement-regulatory proteins (so-called C3 nephritic factors) leading to increased complement activation. The group includes dense deposit disease (DDD) and C3 glomerulonephritis. The two entities are distinguished on the basis of the immunohistological pattern of C3 and the electron microscopy detection of ribbon-like electron-dense deposits in the glomerular basement membrane in DDD, versus deposits of usual density in C3 glomerulonephritis.

MalaCards based summary : Membranoproliferative Glomerulonephritis, also known as mesangiocapillary glomerulonephritis, is related to complement factor h deficiency and dense deposit disease. An important gene associated with Membranoproliferative Glomerulonephritis is C3 (Complement C3), and among its related pathways/superpathways are Complement and coagulation cascades and Innate Immune System. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and eye, and related phenotypes are hypertension and proteinuria

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 54370 Definition Membranoproliferative glomerulonephritis (MPGN) is a chronic progressive kidney disorder characterized by glomerular capillary wall structural changes and mesangial cell proliferation leading to nephrotic syndrome, hypocomplementemia, hypertension, proteinuria and end-stage kidney disease. MPGN can be due to either idiopathic (type 1, 2 and 3 MPGN; see these terms) or secondary (associated with infectious and immune complex diseases ) causes.

Wikipedia : 73 Membranoproliferative glomerulonephritis (MPGN) is a type of glomerulonephritis caused by deposits in... more...

Related Diseases for Membranoproliferative Glomerulonephritis

Diseases related to Membranoproliferative Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)
# Related Disease Score Top Affiliating Genes
1 complement factor h deficiency 32.5 CFH CD46
2 dense deposit disease 32.2 DGKE CFHR5 CFHR2 CFH CFB C3
3 proteinuria, chronic benign 31.6 NPHS1 CD79A ALB
4 cryoglobulinemia 31.5 TSLP IFNA1 CD79A
5 glomerular disease 31.4 CD79A ALB
6 cryoglobulinemia, familial mixed 31.4 TSLP IFNA1
7 c3 glomerulopathy 31.2 DGKE CFP CFHR5 CFHR2 CFH CFB
8 nephrotic syndrome 30.9 WT1 PON1 NPHS1 DGKE CD79A C3
9 vasculitis 30.9 ITGB2 ICAM1 CD79A C3
10 autoimmune disease 30.8 ITGAL IFNA1 CD79A C4A C3
11 membranous nephropathy 30.7 WT1 NPHS1 CD79A C3 ALB
12 diffuse glomerulonephritis 30.5 CFP C3
13 arteriolosclerosis 30.5 CD79A C3 ALB
14 complement component 2 deficiency 30.5 CFH CFB C4A
15 focal segmental glomerulosclerosis 30.4 WT1 PON1 NPHS1 ALB
16 autoimmune enteropathy 30.3 ITGAL ICAM1
17 glomerulonephritis 30.3 NPHS1 ITGAL ICAM1 CFP CFHR5 CFH
18 retinal disease 30.3 PON1 CFH CFB ALB
19 acute proliferative glomerulonephritis 30.3 NPHS1 C3 ALB
20 severe pre-eclampsia 30.2 CFH CFB C3 ALB
21 immune-complex glomerulonephritis 30.2 ITGAL ICAM1 CFHR2 C3 ALB
22 pyuria 30.1 C3 ALB
23 acquired immunodeficiency syndrome 30.1 IFNA1 ICAM1 CD79A ALB
24 congenital syphilis 30.1 NPHS1 CD79A
25 thrombotic thrombocytopenic purpura 30.0 CFH CD46 C3
26 kidney disease 30.0 WT1 PON1 NPHS1 CFHR5 CFH CD79A
27 proteasome-associated autoinflammatory syndrome 1 30.0 IFNA1 ICAM1 ALB
28 goodpasture syndrome 30.0 NPHS1 CFP ALB
29 meningococcal meningitis 30.0 CFP CFHR2 CFH
30 otitis media 30.0 ICAM1 CD79A C3 ALB
31 rapidly progressive glomerulonephritis 30.0 NPHS1 ICAM1 CFP C3 ALB
32 type 1 diabetes mellitus 29.9 PON1 ICAM1 CD79A C4A ALB
33 acute poststreptococcal glomerulonephritis 29.9 CFP CFHR5 CFHR2 CD79A C3 ALB
34 bacterial infectious disease 29.9 ITGB2 CFP CFHR2 C4A
35 alport syndrome 29.9 NPHS1 CFHR5 CFH ALB
36 peritonitis 29.9 ITGB2 ICAM1 ALB
37 end stage renal disease 29.7 PON1 NPHS1 ICAM1 CFHR5 CFH CD46
38 diarrhea 29.7 IFNA1 CD46 C3 ALB
39 hemolytic-uremic syndrome 29.6 DGKE CFHR5 CFHR2 CFH CFB CD46
40 genetic atypical hemolytic-uremic syndrome 29.6 DGKE CFHR5 CFH CFB CD46 C3
41 lyme disease 29.6 IFNA1 CFHR2 CFH C4A C3
42 myocarditis 29.5 ITGB2 IFNA1 ICAM1
43 iga glomerulonephritis 29.4 NPHS1 ICAM1 CFP CFHR2 CFH CD79A
44 meningitis 29.4 ICAM1 CFP CD46 C3 ALB
45 complement component 3 deficiency 29.3 CFP CFHR2 CFH CD46 C4A C3
46 chronic kidney disease 29.2 WT1 PON1 NPHS1 ICAM1 CFHR5 CFH
47 hemolytic anemia 29.1 IFNA1 DGKE CFHR5 CFH CFB CD46
48 hemolytic uremic syndrome, atypical 1 28.9 DGKE CFP CFHR5 CFHR2 CFH CFB
49 macular degeneration, age-related, 1 28.9 ICAM1 CFP CFHR5 CFHR2 CFH CFB
50 complement deficiency 28.7 DGKE CFP CFHR5 CFHR2 CFH CFB

Graphical network of the top 20 diseases related to Membranoproliferative Glomerulonephritis:



Diseases related to Membranoproliferative Glomerulonephritis

Symptoms & Phenotypes for Membranoproliferative Glomerulonephritis

Human phenotypes related to Membranoproliferative Glomerulonephritis:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0000822
2 proteinuria 58 31 frequent (33%) Frequent (79-30%) HP:0000093
3 nephrotic syndrome 58 31 frequent (33%) Frequent (79-30%) HP:0000100
4 microscopic hematuria 58 31 frequent (33%) Frequent (79-30%) HP:0002907
5 decreased serum complement c3 58 31 frequent (33%) Frequent (79-30%) HP:0005421
6 glomerular subendothelial electron-dense deposits 58 31 frequent (33%) Frequent (79-30%) HP:0004746
7 c3 nephritic factor positivity 58 31 frequent (33%) Frequent (79-30%) HP:0030888
8 hypoalbuminemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003073
9 acute kidney injury 58 31 occasional (7.5%) Occasional (29-5%) HP:0001919
10 stage 5 chronic kidney disease 58 31 occasional (7.5%) Occasional (29-5%) HP:0003774
11 myocardial infarction 58 31 very rare (1%) Very rare (<4-1%) HP:0001658
12 abnormal thrombosis 58 31 very rare (1%) Very rare (<4-1%) HP:0001977
13 drusen 58 31 very rare (1%) Very rare (<4-1%) HP:0011510
14 renal insufficiency 58 Frequent (79-30%)
15 chronic kidney disease 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Membranoproliferative Glomerulonephritis according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.64 DGKE
2 Decreased viability GR00055-A-2 9.64 DGKE
3 Decreased viability GR00221-A-1 9.64 DGKE
4 Decreased viability GR00221-A-2 9.64 DGKE
5 Decreased viability GR00221-A-3 9.64 DGKE
6 Decreased viability GR00240-S-1 9.64 DGKE ICAM3 PON1
7 Decreased viability GR00249-S 9.64 ALB CD79A DGKE ICAM1
8 Decreased viability GR00301-A 9.64 DGKE
9 Decreased viability GR00381-A-1 9.64 CD79A CFHR5 WT1
10 Decreased viability GR00381-A-3 9.64 CD79A
11 Decreased viability GR00386-A-1 9.64 ALB C3 CD79A CFHR5

MGI Mouse Phenotypes related to Membranoproliferative Glomerulonephritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ALB C3 CD79A CFB CFH CFP
2 immune system MP:0005387 9.7 ALB C3 CD79A CFB CFH CFP
3 normal MP:0002873 9.28 ALB C3 CD79A CFB CFH CFP

Drugs & Therapeutics for Membranoproliferative Glomerulonephritis

Drugs for Membranoproliferative Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
3 Immunosuppressive Agents Phase 3
4 Antifungal Agents Phase 3
5 Calcineurin Inhibitors Phase 3
6 Cyclosporins Phase 3
7 Anti-Infective Agents Phase 3
8 Dermatologic Agents Phase 3
9
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
10
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
11
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
12
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
13
Mycophenolic acid Approved Phase 2 24280-93-1 446541
14
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
15
belimumab Approved Phase 2 356547-88-1 5957 10451420
16
Enalapril Approved, Vet_approved Phase 2 75847-73-3 5362032 40466924
17
Enalaprilat Approved Phase 2 76420-72-9 6917719
18
Daratumumab Approved Phase 2 945721-28-8
19
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
20 Immunoglobulins Phase 2
21 Antibodies Phase 2
22 Autoantibodies Phase 2
23 Methylprednisolone Acetate Phase 2
24 Angiotensin-Converting Enzyme Inhibitors Phase 2
25 Antihypertensive Agents Phase 2
26 HIV Protease Inhibitors Phase 2
27
protease inhibitors Phase 2
28 Antigen-Antibody Complex Phase 2
29 Immunoglobulin A Phase 2
30 Complement System Proteins Phase 2
31
rituximab Approved Phase 1 174722-31-7 10201696
32
Aspirin Approved, Vet_approved Phase 1 50-78-2 2244
33 Immunologic Factors Phase 1
34 Antineoplastic Agents, Immunological Phase 1
35 Antirheumatic Agents Phase 1
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
2 EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA Completed NCT02093533 Phase 2 Eculizumab
3 A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Completed NCT03124368 Phase 2 ACH-0144471
4 An Open-Label, Multiple-Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BG9588 (Anti-CD40L Antibody) in Subjects With Proliferative Lupus Glomerulonephritis (SLE-GN) Completed NCT00001789 Phase 2 BG9588
5 A Randomized Trial to Investigate the Reset of Humoral Autoimmunity by Combining Belimumab With Rituximab in Severe Systemic Lupus Erythematosus Recruiting NCT03747159 Phase 2 Belimumab Injection
6 A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy Recruiting NCT03301467 Phase 2 Avacopan;Avacopan Matching Placebo
7 Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy Recruiting NCT04183101 Phase 2 Aliskiren;Enalapril
8 A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease Recruiting NCT02682407 Phase 2
9 An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471 Active, not recruiting NCT03459443 Phase 2 ACH-0144471
10 Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy Active, not recruiting NCT03095118 Phase 2 Daratumumab
11 A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) Active, not recruiting NCT03453619 Phase 2 APL-2
12 A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G) Active, not recruiting NCT03369236 Phase 2 ACH-0144471;Placebo
13 An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN Not yet recruiting NCT04572854 Phase 2 Pegcetacoplan
14 Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis Completed NCT00275613 Phase 1 Rituximab
15 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Completed NCT01221181 Phase 1 Eculizumab
16 A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease Terminated NCT01791686 Phase 1 CDX-1135
17 Sulodexide Treatment in Patients With Dense Deposit Disease Withdrawn NCT00583427 Phase 1 Sulodexide
18 A Pilot, Open-Label Single Center Trial of TP10 in Pediatric and Adult Patients With C3 Glomerulopathy (C3G) Withdrawn NCT02302755 Phase 1 TP10
19 Sub-project of the Clinical Protocol ACH471-205 "An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471" Active, not recruiting NCT03723512

Search NIH Clinical Center for Membranoproliferative Glomerulonephritis

Cochrane evidence based reviews: glomerulonephritis, membranoproliferative

Genetic Tests for Membranoproliferative Glomerulonephritis

Genetic tests related to Membranoproliferative Glomerulonephritis:

# Genetic test Affiliating Genes
1 Mesangiocapillary Glomerulonephritis 29

Anatomical Context for Membranoproliferative Glomerulonephritis

MalaCards organs/tissues related to Membranoproliferative Glomerulonephritis:

40
Kidney, Heart, Eye, Myeloid, Liver, Endothelial, Lymph Node

Publications for Membranoproliferative Glomerulonephritis

Articles related to Membranoproliferative Glomerulonephritis:

(show top 50) (show all 2458)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
2
Autoimmune kidney diseases. 54 61
19906361 2010
3
Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature. 61 54
19169768 2009
4
The dot-and-fleck retinopathy of X linked Alport syndrome is independent of complement factor H (CFH) gene polymorphisms. 54 61
19019939 2009
5
Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. 54 61
18336910 2008
6
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. 54 61
18070148 2008
7
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. 61 54
18081690 2008
8
All-trans-retinoic acid aggravates cryoglobulin-associated membranoproliferative glomerulonephritis in mice. 61 54
17686814 2007
9
Loss of self-control in the complement system and innate autoreactivity. 54 61
17785294 2007
10
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. 61 54
17517971 2007
11
Complement factor H and the hemolytic uremic syndrome. 54 61
17548524 2007
12
Meningococcal disease associated with an acute post-streptococcal complement deficiency. 54 61
17294226 2007
13
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. 61 54
17089378 2007
14
The simple design of complement factor H: Looks can be deceiving. 54 61
16919753 2007
15
Complement factor H: spatial and temporal expression and localization in the eye. 54 61
16936129 2006
16
Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). 54 61
16299065 2006
17
Characterization of kidney lesions in Indian adults: towards a renal biopsy registry. 61 54
16736422 2006
18
Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. 54 61
16023208 2006
19
An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. 54 61
16281287 2006
20
Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. 54 61
15086460 2004
21
Growth factor expression in a murine model of cryoglobulinemia. 61 54
12631122 2003
22
Frequency of renal pathology in Spain 1994-1999. 54 61
12198210 2002
23
Patterns of nephrin and a new proteinuria-associated protein expression in human renal diseases. 54 61
11786094 2002
24
Transjugular renal biopsy in patients with liver disease. 54 61
11382682 2001
25
[A case of cryoglobulinemic membranoproliferative glomerulonephritis associated with chronic hepatitis C which was effectively treated by interferon alpha-2b]. 54 61
11400287 2001
26
Expression of nephrin in pediatric kidney diseases. 61 54
11158218 2001
27
Changing incidence of glomerular diseases in adults. 61 54
10793022 2000
28
Glomerular deposition of mannose-binding lectin in human glomerulonephritis. 61 54
10328463 1999
29
Hypercholesterolemia and glomerular diseases in urinary screening of school children. 61 54
10228998 1999
30
Tubulointerstitial mast cell infiltration in glomerulonephritis. 54 61
9774120 1998
31
[An electron microscopic study of circumferential mesangial interposition in various renal diseases]. 61 54
9654910 1998
32
In situ complement activation in porcine membranoproliferative glomerulonephritis type II. 61 54
9461093 1998
33
Glomerulonephritis in childhood. 54 61
9204243 1997
34
Distribution of extracellular matrix receptors in various forms of glomerulonephritis. 61 54
7538261 1995
35
Recurrent diseases in the kidney transplant. 61 54
8023819 1994
36
An immunohistochemical study of extracellular matrix components and integrins in human glomerular diseases. 54 61
8022108 1994
37
Primary glomerulonephritis with detectable glomerular hepatitis B virus antigens. 54 61
8291656 1994
38
Histone-reactive IgA antibodies in adult IgA nephropathy and other primary glomerulonephritis. 54 61
7527503 1994
39
Activated C3 (C3b) in the nephritic glomerulus. 54 61
8398646 1993
40
[Wilson disease, IgA glomerulonephritis and vascular purpura: an incidental association?]. 61 54
8135612 1993
41
Nucleotide sequence of a human autoantibody to the alternative pathway C3/C5 convertase (C3NeF). 61 54
8395463 1993
42
[Glomerular permeability for serum proteins in different morphological types of primary chronic glomerulopathy]. 54 61
8378840 1993
43
[Studies on Hanganutziu-Deicher antibodies in renal diseases]. 61 54
1316976 1992
44
Double monoclonal cryoglobulinemia, glomerulonephritis and lymphoma. 61 54
1300443 1992
45
Renal expression of intercellular adhesion molecule-1 in different forms of glomerulonephritis. 61 54
1682080 1991
46
[Membranoproliferative glomerulonephritis with semilunar forms and massive deposits of IgA associated with HBsAg]. 54 61
2292914 1990
47
Predictors of poor kidney outcome in children with C3 glomerulopathy. 61
33130981 2021
48
First case report of monoclonal IgG3-heavy-chain glomerulonephritis with microtubular structures. 61
33156494 2021
49
Progression of proliferative glomerulonephritis with monoclonal IgG deposits in pediatric patients. 61
33044675 2021
50
IgM-MGUS and associated membranoproliferative glomerulonephritis during IVIG administration. 61
32363418 2021

Variations for Membranoproliferative Glomerulonephritis

ClinVar genetic disease variations for Membranoproliferative Glomerulonephritis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 C3 NM_000064.4(C3):c.3085G>A (p.Asp1029Asn) SNV Likely pathogenic 812882 rs1599507415 GRCh37: 19:6694511-6694511
GRCh38: 19:6694500-6694500
2 overlap with 2 genes Deletion Likely pathogenic 813262 GRCh37: 1:196498350-196626665
GRCh38:

Expression for Membranoproliferative Glomerulonephritis

Search GEO for disease gene expression data for Membranoproliferative Glomerulonephritis.

Pathways for Membranoproliferative Glomerulonephritis

Pathways related to Membranoproliferative Glomerulonephritis according to KEGG:

36
# Name Kegg Source Accession
1 Complement and coagulation cascades hsa04610

Pathways related to Membranoproliferative Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 ITGB2 ITGAL IFNA1 ICAM3 ICAM1 CFP
2
Show member pathways
12.65 ITGB2 ITGAL IFNA1 ICAM1 C4A C3
3
Show member pathways
12.34 ITGB2 ITGAL IFNA1 ICAM1
4
Show member pathways
11.99 ITGB2 ITGAL ICAM3 ICAM1
5 11.95 ITGB2 ITGAL ICAM3 ICAM1
6
Show member pathways
11.93 CFH CFB CD46 C4A C3
7
Show member pathways
11.9 ITGB2 CFP CFH CFB CD46 C4A
8 11.85 ITGB2 ITGAL ICAM3 ICAM1 C3
9 11.7 ITGB2 ITGAL ICAM1
10 11.65 ITGB2 ITGAL C3
11
Show member pathways
11.61 CFP CFB C4A C3
12 11.59 ITGB2 C4A C3
13 11.52 ITGB2 ITGAL ICAM1
14 11.48 ITGB2 ITGAL ICAM1 CFH CFB C4A
15 11.39 ITGB2 ITGAL ICAM1
16 11.39 ITGB2 CFHR5 CFHR2 CFH CFB CD46
17 11.2 ITGB2 ITGAL ICAM3 ICAM1

GO Terms for Membranoproliferative Glomerulonephritis

Cellular components related to Membranoproliferative Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10 TSLP PON1 IFNA1 CFP CFHR5 CFHR2
2 extracellular space GO:0005615 9.85 TSLP PON1 IFNA1 ICAM1 CFP CFH
3 cell surface GO:0009986 9.8 ITGB2 ITGAL ICAM1 CD46 C3
4 extracellular exosome GO:0070062 9.73 PON1 NPHS1 ITGB2 ITGAL ICAM3 ICAM1
5 endoplasmic reticulum lumen GO:0005788 9.67 CFP C4A C3 ALB
6 integrin alphaL-beta2 complex GO:0034687 9.32 ITGB2 ITGAL
7 blood microparticle GO:0072562 9.1 PON1 CFH CFB C4A C3 ALB

Biological processes related to Membranoproliferative Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.93 CFP CFH CFB CD46 C4A C3
2 immune system process GO:0002376 9.91 CFP CFH CFB CD79A CD46 C4A
3 extracellular matrix organization GO:0030198 9.84 ITGB2 ITGAL ICAM3 ICAM1
4 regulation of immune response GO:0050776 9.72 ITGB2 ITGAL ICAM3 ICAM1 C3
5 phagocytosis GO:0006909 9.67 ITGB2 ITGAL ICAM3
6 cell-cell adhesion GO:0098609 9.65 NPHS1 ITGB2 ITGAL ICAM3 ICAM1
7 leukocyte cell-cell adhesion GO:0007159 9.58 ITGB2 ITGAL ICAM1
8 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.56 ITGB2 ICAM1
9 amyloid-beta clearance GO:0097242 9.55 ITGB2 C3
10 complement activation GO:0006956 9.55 CFP CFH CFB C4A C3
11 cytolysis by host of symbiont cells GO:0051838 9.52 CFHR5 CFHR2
12 glomerular basement membrane development GO:0032836 9.51 WT1 NPHS1
13 positive regulation of apoptotic cell clearance GO:2000427 9.48 C4A C3
14 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell GO:0002291 9.43 ITGAL ICAM1
15 complement activation, alternative pathway GO:0006957 9.35 CFP CFHR5 CFH CFB C3
16 regulation of complement activation GO:0030449 9.23 CFP CFHR5 CFHR2 CFH CFB CD46

Molecular functions related to Membranoproliferative Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion molecule binding GO:0050839 9.13 NPHS1 ITGB2 ITGAL
2 ICAM-3 receptor activity GO:0030369 8.62 ITGB2 ITGAL

Sources for Membranoproliferative Glomerulonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....